Who
Elena Ridloff
CFO and CBO
Company insider
Files Form 4 as: CFO and CBO, Sionna Therapeutics; Director, Immunic; Director, Kymera Therapeutics; Director, Kronos Bio; EVP and CFO, ACADIA Pharmaceuticals.
In numbers
- Trades disclosed
- 98
- Buys
- 1
- Sells
- 18
- Bought
- $50K
- Sold
- $7.8M
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 1 Apr 2019
- Last trade
- 17 Sep 2026
- Last filed
- 18 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Sep 2026filed 18 Sep 2026 | SION Sionna TherapeuticsBiotechnology | SEC FORM 4 Code A | —47,269 at $0.00 | filing |
| 17 Sep 2026filed 18 Sep 2026 | SION Sionna TherapeuticsBiotechnology | SEC FORM 4 Code A | —47,268 at $0.00 | filing |
| 17 Sep 2026filed 18 Sep 2026 | SION Sionna Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —165,440 at $0.00 | filing |
| 17 Sep 2026filed 18 Sep 2026 | SION Sionna Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —165,440 at $0.00 | filing |
| 17 Sep 2026filed 18 Sep 2026 | SION Sionna Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —165,440 at $0.00 | filing |
| 17 Sep 2026filed 18 Sep 2026 | SION Sionna Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —165,440 at $0.00 | filing |
| 17 Sep 2026filed 18 Sep 2026 | SION Sionna TherapeuticsBiotechnology | SEC FORM 4 Code A | —47,269 at $0.00 | filing |
| 17 Sep 2026filed 18 Sep 2026 | SION Sionna TherapeuticsBiotechnology | SEC FORM 4 Code A | —47,268 at $0.00 | filing |
| 6 Aug 2026filed 10 Aug 2026 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,740 at $0.00 | filing |
| 6 Aug 2026filed 10 Aug 2026 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,740 at $0.00 | filing |
| 24 Jun 2026filed 25 Jun 2026 | KYMR Kymera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,068 at $0.00 | filing |
| 24 Jun 2026filed 25 Jun 2026 | KYMR Kymera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,068 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Code M | $94K3,000 at $31.20 | filing |
| 11 May 2026filed 11 May 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $261K3,000 at $87.00 | filing |
| 11 May 2026filed 11 May 2026 | KYMR Kymera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | KYMR Kymera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 11 May 2026filed 11 May 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Code M | $94K3,000 at $31.20 | filing |
| 11 May 2026filed 11 May 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $261K3,000 at $87.00 | filing |
| 1 Apr 2026filed 1 Apr 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Code M | $65K4,600 at $14.18 | filing |
| 1 Apr 2026filed 1 Apr 2026 | KYMR Kymera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,600 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.